A Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): IMvigor130

Introduction and Objectives: First-line (1L) treatment (tx) for mUC includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending on patient (pt)- and tumour-specific factors. IMvigor130 is a Phase 3, global, randomised, study of atezo (anti–PD-L1) alone or +PBC vs placebo+PBC in untreated mUC. Materials and Methods: 1213 PBC-eligible mUC